The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study.
Fabrice Andre
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Patrick Neven
No relevant relationships to disclose
Antonino Musolino
No relevant relationships to disclose
Luciano Latini
No relevant relationships to disclose
Mario Campone
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Novartis; Roche
Carlos H. Barrios
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Matthew Squires
Employment or Leadership Position - Novartis
Yong Zhang
Employment or Leadership Position - Novartis
Stephanie Deudon
Employment or Leadership Position - Novartis
Alejandro Javier Yovine
Employment or Leadership Position - Novartis
Kimberly L. Blackwell
No relevant relationships to disclose